Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes

Novo Nordisk A/S277 enrolled

Overview

This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

277

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

insulin NPHDRUG

insulin aspartDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HbA1c: 7.5-11.0% * BMI: 25-40 kg/m2 Exclusion Criteria: * Treatment with any OAD (Oral Antidiabetic Drugs) except metformin

Locations (1)

Unnamed facility

A Coruña, Spain

Outcomes

Primary Outcomes

Body weight loss

Time frame: after 26 weeks of treatment

Secondary Outcomes

HbA1c

Incidence of hypoglycaemia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.